MyMD Pharmaceuticals, Inc.
855 N. Wolfe Street, Suite 623
Baltimore, MD 21205
May 10, 2021
U.S. Securities and Exchange Commission
Division of Corporation Finance
Securities and Exchange Commission
Washington, D.C. 20549
|Attention:||Ms. Margaret Schwartz|
|Mr. Joe McCann|
|Re:||MyMD Pharmaceuticals, Inc., f/k/a Akers Biosciences, Inc.|
|Registration Statement on Form S-3|
|Originally filed on March 25, 2021, as amended on April 28, 2021|
|File No. 333-254698 (the “Registration Statement”)|
|Request for Acceleration|
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, MyMD Pharmaceuticals, Inc. (f/k/a Akers Biosciences, Inc., the “Company”) hereby respectfully requests acceleration of the effective date of the Registration Statement, as amended, so that it may become effective at 4:00 p.m., Eastern Time, on May 11, 2021, or as soon thereafter as practicable.
Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
|Very truly yours,|
|MYMD PHARMACEUTICALS, INC.|
|By:||/s/ Chris Chapman|
President, Chief Medical Officer, and Director
cc: Rick A. Werner, Esq., Haynes and Boone, LLP